CVS Caremark Names Keith Reynolds Chief Growth Officer

By Healthcare Technology News · August 8, 2026

CVS Caremark, the pharmacy benefit manager owned by CVS Health, is adding Keith Reynolds as chief growth officer, according to an Aug. 7 LinkedIn post cited by Becker's Hospital Review. Chief Sales Officer Jim Fowler is transitioning into retirement.

Reynolds is an internal promotion with deep roots at the company. He spent 25 years across CVS Health and Aetna and most recently served as a chief operating officer. That continuity signals CVS wants an insider to protect and expand Caremark's client base rather than shift strategy under an outsider.

The move lands as PBMs face intense pressure. Caremark, along with rivals Express Scripts and Optum Rx, is under fire from the Federal Trade Commission, Congress, and employers over drug pricing and rebate practices. A growth chief must defend market share while the business model itself is being challenged by regulators and by newer transparent-pricing competitors. How Reynolds balances expansion with mounting political risk will be worth watching.

Judge Sends Ballad Health's UnitedHealth MA Suit to Arbitration

A federal judge dismissed Ballad Health's Medicare Advantage lawsuit against UnitedHealth, ordering the payment dispute into arbitration.

Why it matters: Arbitration clauses in payer contracts can quietly steer provider-insurer disputes out of court, shaping how health systems fight Medicare Advantage denials.

September 15, 2026

Payers

Medicare Advantage Plans Rethink Post-Discharge Care Transitions

Medicare Advantage plans are refocusing on the post-discharge period to reduce readmissions and protect Star Ratings.

Why it matters: Star Ratings drive billions in bonus payments and enrollment, and better care transitions are becoming a key way plans defend those scores.

September 8, 2026

Payers

Vertical Integration Is Quietly Inflating Patient Bills

KFF Health News details how vertical integration across hospitals, insurers, and pharmacies steers patients toward higher-priced care and inflates their bills.

Why it matters: As a handful of integrated companies control care, coverage, and drugs, patients face higher costs with little visibility into why.